uniQure (NASDAQ:QURE) Price Target Raised to $110.00

uniQure (NASDAQ:QURE) had its price target raised by research analysts at HC Wainwright from $70.00 to $110.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 100.29% from the company’s current price.

QURE has been the subject of several other reports. Guggenheim raised their price objective on uniQure from $28.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Wells Fargo & Company increased their target price on shares of uniQure from $65.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday. Cantor Fitzgerald lifted their price target on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Royal Bank Of Canada reiterated an “outperform” rating on shares of uniQure in a research note on Wednesday, September 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research note on Saturday, September 27th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $71.75.

uniQure Stock Up 0.8%

QURE stock opened at $54.92 on Monday. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. The company has a market cap of $3.01 billion, a price-to-earnings ratio of -14.01 and a beta of 0.56. The business’s 50-day moving average is $21.59 and its two-hundred day moving average is $16.40. uniQure has a fifty-two week low of $4.82 and a fifty-two week high of $60.70.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million for the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. As a group, analysts forecast that uniQure will post -3.75 earnings per share for the current year.

Insider Buying and Selling

In other uniQure news, CFO Christian Klemt sold 15,000 shares of the stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the transaction, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. This trade represents a 6.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 226,316 shares of the business’s stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares in the company, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 244,316 shares of company stock valued at $10,328,181 over the last three months. Corporate insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several large investors have recently modified their holdings of QURE. Cubist Systematic Strategies LLC purchased a new stake in shares of uniQure in the 1st quarter worth $2,562,000. OMERS ADMINISTRATION Corp purchased a new position in shares of uniQure in the first quarter valued at approximately $152,000. Assenagon Asset Management S.A. lifted its position in uniQure by 355.2% during the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company’s stock worth $3,550,000 after buying an additional 261,323 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of uniQure in the first quarter valued at $3,218,000. Finally, XTX Topco Ltd grew its stake in uniQure by 127.3% during the 1st quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 20,720 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.